Cannabis and the Heart and Vessels: What the Science Actually Says
A 2024 narrative review published in the Journal of Cellular Physiology maps the evidence linking cannabinoids to vascular disease across multiple conditions and receptor pathways, highlighting both genuine therapeutic promise and the serious evidentiary gaps that prevent confident clinical recommendations.
Why This Matters
Cannabis use is expanding rapidly under liberalized regulatory frameworks, yet clinicians fielding patient questions about cardiovascular safety often lack a consolidated evidence base. The endocannabinoid system is deeply embedded in vascular biology, with receptor subtypes exerting opposing effects on inflammation, smooth muscle proliferation, and arterial remodeling. A comprehensive mapping of what has and has not been established is timely precisely because the gap between public confidence in cannabis safety and the actual state of vascular evidence is widening.
Clinical Summary
The endocannabinoid system modulates vascular function through at least four receptor families: CB1 and CB2 cannabinoid receptors, transient receptor potential vanilloid channels (TRPV1 and TRPV4), and orphan G-protein-coupled receptors GPR18 and GPR55. These receptors are expressed on vascular smooth muscle cells, endothelial cells, macrophages, and platelets, positioning them as regulators of atherosclerosis, vascular tone, and arterial remodeling. A 2024 narrative review by researchers funded through the Henan Medical Science Program and the Canadian Institutes of Health Research, published in the Journal of Cellular Physiology, synthesizes preclinical experiments, clinical case series, and observational studies to map what is known about cannabinoid involvement in atherosclerosis, arteritis, vasospasm, arterial dissection, pulmonary arterial hypertension, and in-stent restenosis.
The review’s strongest findings concern the opposing roles of CB1 and CB2 in atherosclerosis. Animal data and some human coronary artery disease studies suggest CB1 activation promotes plaque formation and smooth muscle proliferation, while CB2 activation appears atheroprotective. Cannabidiol (CBD) shows preclinical efficacy against pulmonary arterial hypertension through anti-inflammatory and mitochondrial mechanisms. However, associations between cannabis use and arteritis, vasospasm, and spontaneous dissection derive almost entirely from case reports and small observational studies, predominantly in young men. The review notes that the CB1 antagonist rimonabant improved metabolic risk factors but was withdrawn due to psychiatric adverse effects, illustrating the translation gap. The authors conclude that human trial data for most cannabinoid-vascular interactions are absent and that rigorous prospective studies are needed before clinical applications can be pursued.
Dr. Caplan’s Take
This review does something genuinely useful: it organizes a sprawling and fragmented literature into a legible map. The mechanistic work on CB1 and CB2 in atherosclerosis is converging from multiple lines of preclinical evidence, and the CBD data in pulmonary hypertension models are intriguing. But the honest clinical reality is that almost none of this has been tested in the kinds of human trials that would let me change a recommendation. Patients who use cannabis regularly ask me whether it is harming their arteries, and the truthful answer is that we have biological plausibility and case-level signals, not proof.
In practice, I take a cardiovascular history seriously in every cannabis-using patient and pay particular attention to younger patients presenting with unexplained arterial events. I do not tell patients that cannabis is cardiovascularly safe, nor do I overstate the risk beyond what the evidence supports. When patients ask about CBD for vascular conditions, I explain that the preclinical data are promising but that no human efficacy data exist. The most defensible position right now is informed caution paired with ongoing monitoring.
Clinical Perspective
This review sits early in the research arc for most of the vascular conditions it covers. The atherosclerosis data have progressed furthest, with converging animal models and mechanistic coherence, but even here, large prospective human studies confirming causal relationships between cannabis exposure and accelerated plaque formation are lacking. For arteritis, vasospasm, and dissection, the evidence base consists of case reports and small series, which can generate hypotheses but cannot establish prevalence, dose-response relationships, or mechanisms. Clinicians should not dismiss these associations, but they should not present them to patients as established causal links either.
From a pharmacological standpoint, the rimonabant experience is instructive: CB1 receptors in the central nervous system mediate mood and reward, so systemic CB1 blockade carries psychiatric risk that may be unacceptable even when metabolic benefits are real. The development of peripherally restricted CB1 antagonists is a plausible next step but remains preclinical. CBD’s favorable safety profile makes it an attractive candidate for vascular applications, though drug interactions with anticoagulants and antiplatelet agents via cytochrome P450 inhibition warrant attention in patients with existing vascular disease. The actionable recommendation now is to document cannabis use systematically in patients with unexplained vascular events, particularly in younger demographics, and to include it in differential diagnostic reasoning.
Study at a Glance
- Study Type
- Narrative review
- Population
- Preclinical models (rodent, in vitro) and human clinical case series and observational cohorts
- Intervention
- Phytocannabinoids, synthetic cannabinoids, and endocannabinoids acting on vascular targets
- Comparator
- Not applicable (narrative synthesis, no controlled comparison)
- Primary Outcomes
- Vascular disease associations and mechanisms across atherosclerosis, arteritis, vasospasm, dissection, pulmonary arterial hypertension, and in-stent restenosis
- Sample Size
- Not applicable (review of heterogeneous literature)
- Journal
- Journal of Cellular Physiology
- Year
- 2024
- DOI
- 10.1002/jcp.31373
- Funding Source
- Henan Medical Science Program; Canadian Institutes of Health Research
What Kind of Evidence Is This
This is a narrative review, which occupies a position below systematic reviews and meta-analyses in the evidence hierarchy. It synthesizes preclinical experiments, case reports, and observational studies without a described systematic search strategy or meta-analytic framework. The most important inference constraint this imposes is that the completeness and representativeness of the included evidence cannot be independently verified, meaning relevant contradictory findings may have been inadvertently omitted.
How This Fits With the Broader Literature
The review’s atherosclerosis findings are consistent with prior work by Steffens and colleagues (2005) demonstrating CB2-mediated atheroprotection in apolipoprotein E-knockout mice, and with epidemiological signals from the Behavioral Risk Factor Surveillance System linking cannabis use to increased cardiovascular event rates. The CBD findings in pulmonary hypertension models align with Sadowska and colleagues’ preclinical work but remain without clinical confirmation. The arteritis associations echo decades of scattered case reports dating to the 1960s, but this literature has not advanced meaningfully beyond the case-report level, a stagnation this review acknowledges but cannot resolve.
Common Misreadings
The most likely overinterpretation is reading this review as evidence that cannabis causes arteritis, vasospasm, or arterial dissection. The underlying data for these associations consist almost entirely of case reports in which cannabis use preceded the vascular event, but temporal association in uncontrolled observations cannot establish causation. Confounders such as tobacco co-use, contaminants in illicit cannabis products, and unmeasured genetic susceptibility remain unaddressed. Equally, the therapeutic promise of CBD for pulmonary hypertension should not be read as clinical readiness; all efficacy data are from rodent models with no human trial replication.
Bottom Line
This review consolidates what is known about cannabinoid-vascular interactions into a useful clinical reference, but it confirms that most associations beyond atherosclerosis mechanistic data rest on weak evidentiary foundations. It does not establish causation for cannabis-associated vascular events nor clinical efficacy for cannabinoid-based therapies. For practice today, it supports systematic documentation of cannabis use in patients with unexplained vascular presentations and informed, evidence-proportionate counseling.
References
- Review article discussed: Journal of Cellular Physiology, 2024. DOI: 10.1002/jcp.31373.
- Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 2005;434(7034):782-786.
- Sadowska O, Baranowska-Kuczko M, Gromotowicz-Poplawska A, et al. Cannabidiol in the treatment of pulmonary arterial hypertension: preclinical evidence. Biomedicine & Pharmacotherapy. 2024.
- European Medicines Agency. Withdrawal of rimonabant (Acomplia) marketing authorization. EMA Public Statement, 2009.
Have thoughts on this? Share it:
